The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Chae, Young Kwang ^a,b,c   De Melo Gagliato, Debora ^a,d,e   Pai, Sachin Gopalkrishna ^b,c   Carneiro, Benedito ^b,c   Mohindra, Nisha ^c   Giles, Francis Joseph ^b,c   Ramakrishnan Geethakumari, Praveen ^a   Sohn, Joohyuk ^a   Liu, Shuying ^a   Chen, Huiqin ^a   Ueno, Naoto ^a   Hortobagyi, Gabriel ^a   Gonzalez Angulo, Ana Maria ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HOSPITAL SÍRIO LIBANÊS   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER; TYROSINE;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; BREAST TUMOR; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TRIPLE NEGATIVE BREAST CANCER;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS; TYROSINE;

EID: 84963606510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152585     Document Type: Article

References (37)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA: A cancer journal for clinicians. 2014; 64(1):52-62. doi:10.3322/caac.21203PMID: 24114568.
2. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007; 110(5):973-9. doi:10.1002/cncr.22867 PMID: 17647245.
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251 (4995):802-4. PMID: 1846706.
4. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: Rationale and progress. Nature reviews Cancer. 2012; 12(2):89-103doi:10.1038/nrc3205 PMID: 22270953.
5. Boccaccio C, Comoglio PM. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nature reviews Cancer. 2006; 6(8):637-45. doi:10.1038/nrc1912PMID: 16862193.
6. Blumenschein GR Jr., Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(26):3287-96. doi:10.1200/JCO.2011.40.3774PMID: 22869872; PubMed Central PMCID: PMC3434988.
7. Martin TA, Jiang WG. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anti-cancer agents in medicinal chemistry. 2010; 10(1):2-6. PMID: 20015008.
8. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International journal of cancer Journal international du cancer. 2005; 113(4):678-82. doi:10.1002/ijc.20598PMID: 15455388.
9. Tengs T, Lee JC, Paez JG, Zhao X, LaFramboise T, Giannoukos G, et al. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer letters. 2006; 239(2):227-33. doi:10.1016/j.canlet.2005.08.007 PMID: 16171945.
10. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer letters. 2008; 265(2):258- 69. doi:10.1016/j.canlet.2008.02.049 PMID: 18395971.
11. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(31):12909-14. doi:10.1073/pnas.0810403106 PMID: 19567831; PubMed Central PMCID: PMC2722304.
12. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer research. 2010; 70(22):9391-401. doi:10.1158/0008-5472.CAN-10-0911 PMID: 20861192.
13. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, et al. cMET and phospho- cMET protein levels in breast cancers and survival outcomes. Clinical cancer research: An official journal of the American Association for Cancer Research. 2012; 18(8):2269-77. doi:10.1158/1078-0432.CCR-11-2830PMID: 22374333; PubMed Central PMCID: PMC3821167.
14. de Melo Gagliato D, Fontes Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, et al. Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical breast cancer. 2014. doi:10.1016/j.clbc.2014.06.001 PMID: 25065564.
15. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer research. 2010; 70(10):3857-60. doi:10.1158/0008-5472.CAN-10-0163 PMID: 20406984; PubMed Central PMCID: PMC2875162.
16. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(2):692-7. doi:10.1073/pnas.0707270105 PMID: 18180459; PubMed Central PMCID: PMC2206598.
17. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clinical cancer research: An official journal of the American Association for Cancer Research. 2011; 17(3):472-82. doi:10.1158/1078-0432.CCR-10-0568 PMID: 21098338; PubMed Central PMCID: PMC3033451.
18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43doi:10.1126/science.1141478 PMID: 17463250.
19. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature medicine. 2012; 18(1):74-82. doi:10.1038/nm.2577 PMID: 22157681; PubMed Central PMCID: PMC3467100.
20. Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, et al. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Molecular cancer research: MCR. 2013; 11(9):1112-21. doi:10.1158/1541-7786.MCR-13-0042PMID: 23825050.
21. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(15): E458. doi:10.1200/JCO.2011.35.2245 PMID: 21502545.
22. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clinical proteomics. 2010; 6(4):129-51. doi:10.1007/s12014-010-9055-y PMID: 21691416; PubMed Central PMCID: PMC3116520.
23. Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, et al. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 2014; 134 (10):2424-36. Epub 2014/03/13. doi:10.1002/ijc.28566 PMID: 24615768.
24. Yan S, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: A meta-analysis of 6010 cases. Diagn Pathol. 2015; 10:62. Epub 2015/06/07. doi:10.1186/s13000-015-0296-y PMID: 26047809; PubMed Central PMCID: PMCPMC4458003.
25. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. European journal of cancer. 2001; 37 Suppl 4:S9-S15. PMID: 11597399.
26. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European journal of cancer. 1993; 29A(7):1018-23. PMID: 8098946.
27. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast cancer research and treatment. 1994; 29(1):117-25. PMID: 7912565.
28. Moerkens M, Zhang Y, Wester L, van de Water B, Meerman JH. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC cancer. 2014; 14:283. doi:10.1186/1471-2407-14-283 PMID: 24758408; PubMed Central PMCID: PMC4021213.
29. Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, et al. Regulation of HGF expression by DeltaEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia. 2013; 15(1):73-84. PMID: 23359207; PubMed Central PMCID: PMC3556940.
30. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Experimental cell research. 2000; 259(1):293-9. doi:10.1006/excr.2000.4967PMID: 10942601.
31. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. The Journal of biological chemistry. 2000; 275(12):8806-11. PMID: 10722725.
32. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. International journal of cancer Journal international du cancer. 1997; 74(3):301-9. PMID: 9221809.
33. Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern pathology: An official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27(9):1212-22. doi:10.1038/modpathol.2013.251PMID: 24406864.
34. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast cancer research and treatment. 2012; 136(2):331-45. doi:10.1007/s10549-012-2289-9 PMID: 23073759; PubMed Central PMCID: PMC3832208.
35. Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(20):2586-92. doi:10.1200/JCO.2012.46.2408 PMID: 23733761.
36. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(21):2615- 23. doi:10.1200/JCO.2010.34.5579 PMID: 22665533; PubMed Central PMCID: PMC3413275.
37. Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, et al. Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. Clinical breast cancer. 2014. doi:10.1016/j.clbc.2014.07.007PMID: 25218708.